CORONA Remedies Limited (NSE:CORONA)
India · Delayed Price · Currency is INR 1,697.00
-4.20 (-0.25%)
At close: May 26, 2026
CORONA Remedies Revenue
In the fiscal year ending March 31, 2026, CORONA Remedies had annual revenue of 14.03B INR with 17.28% growth. CORONA Remedies had revenue of 3.53B in the quarter ending March 31, 2026, with 20.23% growth.
Revenue
14.03B
Revenue Growth
+20.08%
P/S Ratio
7.30
Revenue / Employee
3.12M
Employees
4,500
Market Cap
102.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 14.03B | 2.07B | 17.28% |
| Mar 31, 2025 | 11.96B | 1.82B | 17.93% |
| Mar 31, 2024 | 10.14B | 1.30B | 14.75% |
| Mar 31, 2023 | 8.84B | 2.67B | 43.21% |
| Mar 31, 2022 | 6.17B | 411.66M | 7.14% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 83.46B |
| Granules India | 53.66B |
| Viyash Scientific | 34.20B |
| Caplin Point Laboratories | 21.87B |
| AstraZeneca Pharma India | 21.77B |
| FDC Limited | 20.78B |
| Sanofi India | 17.74B |
| Rubicon Research | 15.98B |